Statement: In contrast to the secondary trial, the primary trial did not record any cases of Skin lymphangitis, Bone marrow suppression or Allergic shock.
Primary_evidence: Adverse Events 1:   Total: 33/132 (25.00%)   Febrile neutropenia 1/132 (0.76%)   Haematotoxicity 1/132 (0.76%)   Neutropenia 1/132 (0.76%)   Sinus bradycardia 1/132 (0.76%)   Tachycardia 1/132 (0.76%)   Abdominal pain 2/132 (1.52%)   Abdominal pain upper 1/132 (0.76%)   Constipation 1/132 (0.76%)   Large intestinal obstruction 1/132 (0.76%)   Nausea 3/132 (2.27%)
Secondary_evidence: Adverse Events 1:   Total: 3/50 (6.00%)   Skin lymphangitis  1/50 (2.00%)   Bone marrow suppression  0/50 (0.00%)   Allergic shock  1/50 (2.00%)   Deep incisional SSI  1/50 (2.00%) Adverse Events 2:   Total: 1/51 (1.96%)   Skin lymphangitis  0/51 (0.00%)   Bone marrow suppression  1/51 (1.96%)   Allergic shock  0/51 (0.00%)   Deep incisional SSI  0/51 (0.00%)